Pulmonary Hypertension among Children and Adolescents with Sickle Cell Anemia: A Systematic Review and Meta-analysis
Pulmonary hypertension (PHT) is a major life-threatening complication associated with sickle cell anemia (SCA). However, there is scarcity of evidence in pooling the knowledge regarding the prevalence of PHT in the pediatric SCA patients. Hence, this systematic review was done to determine the pooled prevalence of PHT among SCA children and adolescents. Until January 2021, systematic searches were conducted in MEDLINE, SCOPUS, Web of Science, ScienceDirect, Cochrane library, and Google Scholar. The listed studies’ caliber was evaluated using the Newcastle Ottawa scale. The results of a meta-analysis using a random-effects model included a pooled prevalence and 95% confidence intervals (CIs). In total, 31 studies with 3686 participants were included in the study. Majority of the included studies (26 out of 31 studies) had low risk of bias. The final pooled prevalence of PHT among children and adolescents with SCA was 22% (95% CI: 18 – 26%). Maximum burden of PHT among SCA children was reported in Europe (26%) and Eastern Mediterranean region, while the least burden was found in Africa (17%). There was a significant heterogeneity found between the studies in our analysis (I2 = 87.8%; P < 0.001). The presence of publication bias indicated by an asymmetrical funnel plot was also found. About one in five children and adolescents with SCA suffer from PHTN. The burden is maximum in Europe followed by Eastern Mediterranean region. Diagnostic and intervention packages targeting these patients should be developed and implemented across the high-risk settings.
[1] World Health Organization. Sickle-Cell Disease and Other Haemoglobin Disorders WHO, Geneva. Available from: https://apps.who.int/iris/bitstream/handle/10665/20890/A59_9-en.pdf?sequence=1&Isallowed=y [Last accessed on 2022 Feb 11].
[2] World Health Organization. Sickle-Cell Disease. WHO, Geneva. Available from: https://www.afro.who.int/health-topics/sickle-cell-disease [Last accessed on 2021 Feb 11].
[3] Gladwin, M.T. Current and Future Therapies of Sickle Cell Anaemia: An Historical Perspective. Hematology Am. Soc. Hematol. Educ. Program, 2018, 176, 417–9.
[4] Haque, A.K.; Gokhale, S.; Rampy, B.A.; Adegboyega, P.; Duarte, A.; Saldana, M.J. Pulmonary Hypertension in Sickle Cell Hemoglobinopathy: A Clinicopathologic Study of 20 Cases. Hum. Pathol., 2002, 33, 1037–43.
[5] Rother, R.P.; Bell, L.; Hillmen, P.; Gladwin, M.T. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin: A Novel Mechanism of Human Disease. JAMA, 2005, 293, 1653–62.
[6] Reiter, C.D.; Wang, X.; Tanus-Santos, J.E.; Hogg, N.; Cannon, R.O 3rd.; Schechter, A.N.; Gladwin, M.T. Cell-Free Hemoglobin Limits Nitric Oxide Bioavailability in Sickle-Cell Disease. Nat. Med., 2002, 8, 1383–9.
[7] Mehari, A.; Gladwin, M.T.; Tian, X.; Machado, R.F.; Kato, G.J. Mortality in Adults With Sickle Cell Disease and Pulmonary Hypertension. JAMA, 2012, 307, 1254–6.
[8] Parent, F.; Bachir, D.; Inamo, J.; Lionnet, F.; Driss, F.; Loko, G.; Habibi, A.; Bennani, S.; Savale, L.; Adnot, S.; Maitre, B.; Yaïci, A.; Hajji, L.; O’Callaghan, D.S.; Clerson, P.; Girot, R.; Galacteros, F.; Simonneau, G. A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease. N. Engl. J. Med., 2011, 365, 44–53.
[9] De Castro, L.M.; Jonassaint, J.C.; Graham, F.L.; Ashley-Koch, A.; Telen, M.J. Pulmonary Hypertension Associated with Sickle Cell Disease: Clinical and Laboratory Endpoints and Disease Outcomes. Am. J. Haematol., 2008, 83, 19–25.
[10] Gladwin, M.T.; Sachdev, V.; Jison, M.L.; Shizukuda, Y.; Plehn, J.F.; Minter, K.; Brown, B.; Coles, W.A.; Nichols, J.S.; Ernst, I.; Hunter, L.A.; Blackwelder, W.C.; Schechter, A.N.; Rodgers, G.P.; Castro, O.; Ognibene, F.P. Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. N. Engl. J. Med., 2004, 350, 886–95.
[11] Ataga, K.I.; Moore, C.G.; Jones, S.; Olajide, O.; Strayhorn, D.; Hinderliter, A.; Orringer, E.P. Pulmonary Hypertension in Patients with Sickle Cell Disease: A Longitudinal Study. Br. J. Haematol., 2006, 134, 109–15.
[12] Castro, O.; Gladwin, M.T. Pulmonary Hypertension in Sickle Cell Disease: Mechanisms, Diagnosis, and Management. Hematol. Oncol. Clin. North. Am., 2005, 19, 881–96.
[13] Allen, K.Y.; Jones, S.; Jackson, T.; DeCost, G.; Stephens, P.; Hanna, B.D.; Cohen, M.S; Smith-Whitley, K.; Mercer-Rosa, L.; Natarajan, S.S. Echocardiographic Screening of Cardiovascular Status in Pediatric Sickle Cell Disease. Pediatr. Cardiol., 2019, 40, 1670–8.
[14] Ambrusko, S.J.; Gunawardena, S.; Sakara, A.; Windsor, B.; Lanford, L.; Michelson, P.; Krishnamurti, L. Elevation of Tricuspid Regurgitant Jet Velocity, a Marker for Pulmonary Hypertension in Children with Sickle Cell Disease. Pediatr. Blood Cancer, 2006, 47, 907–13.
[15] Chinawa, J.M.; Chukwu, B.F.; Chinawa, A.T.; Ossai, E.N.; Ikefuna, A.N.; Aronu, A.E.; Obidike, E.O. Right Ventricular Function among South East Nigeria Children with Sickle Cell Anaemia. BMC Pediatr., 2020, 20, 1.
[16] Colombatti, R.; Maschietto, N.; Varotto, E.; Grison, A.; Grazzina, N.; Meneghello, L.; Teso, S.; Carli, M.; Milanesi, O.; Sainati, L. Pulmonary Hypertension in Sickle Cell Disease Children Under 10 Years of Age: Pulmonary Hypertension in SCD Patients Under 10 Years Old. Br. J. Haematol., 2010, 150, 601–9.
[17] Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Int. J. Surg., 2010, 8, 336–41.
[18] Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle- Ottawa scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute, Ottawa, 2011.
[19] Nyaga, V.N.; Arbyn, M.; Aerts, M.; Metaprop: A Stata Command to Perform Meta-Analysis of Binomial Data. Arch. Public Health, 2014, 72, 39.
[20] Higgins, J.P.; Green, S. editors. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley and Sons, United States, 2011.
[21] Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in Meta- Analysis Detected by a Simple, Graphical Test. BMJ, 1997, 315, 629–34.
[22] Agha, H.; El Tagui, M.; El Ghamrawy, M.; Hady, M.A. The 6-Min Walk Test: An Independent Correlate of Elevated Tricuspid Regurgitant Jet Velocity in Children and Young Adult Sickle Cell Patients. Ann. Hematol., 2014, 93, 1131–8.
[23] Cox, S.E.; Soka, D.; Kirkham, F.J.; Newton, C.R.; Prentice, A.M.; Makani, J.; Younoszai, A.K. Tricuspid Regurgitant Jet Velocity and Hospitalization in Tanzanian Children with Sickle Cell Anemia. Haematologica. 2014, 99, e1.
[24] Dahoui, H.A.; Hayek, M.N.; Nietert, P.J.; Arabi, M.T.; Muwakkit, S.A.; Saab, R.H.; Bissar, A.N.; Jumaa, N.M.; Farhat, F.S.; Dabbous, I.A.; Bitar, F.F.; Abboud, M.R. Pulmonary Hypertension in Children and Young Adults with Sickle Cell Disease: Evidence for Familial Clustering. Pediatr. Blood Cancer, 2010, 54, 398–402.
[25] Eddine, A.C.; Alvarez, O.; Lipshultz, S.E.; Lipshultz, S.E.; Kardon, R.; Arheart, K.; Swaminathan, S. Ventricular Structure and Function in Children with Sickle Cell Disease Using Conventional and Tissue Doppler Echocardiography. Am. J. Cardiol., 2012, 109, 1358–64.
[26] Forrest, S.; Kim, A.; Carbonella, J.; Pashankar, F. Proteinuria is Associated with Elevated Tricuspid Regurgitant Jet Velocity in Children with Sickle Cell Disease. Pediatr. Blood Cancer, 2012, 58, 937–40.
[27] Gordeuk, V.R.; Minniti, C.P.; Nouraie, M.; Campbell, A.D.; Rana, S.R.; Luchtman-Jones, L.; Sable, C.; Dham, N.; Ensing, G.; Prchal, J.T.; Kato, G.J.; Gladwin, M.T.; Castro, O.L. Elevated Tricuspid Regurgitation Velocity and Decline in Exercise Capacity over 22 Months of Follow up in Children and Adolescents with Sickle Cell Anemia. Haematologica, 2011, 96, 33–40.
[28] Gore, S. Study of Prevalence of Pulmonary Hypertension in Children with Sickle Cell Anemia or Sickle Cell Disease. Joint Event Pediatr. Nutr. Prim. Healthc. Nurs., 2018, 8, 42.
[29] Hagar, R.W.; Michlitsch, J.G.; Gardner, J.; Vichinsky, E.P.; Morris, C.R. Clinical Differences between Children and Adults with Pulmonary Hypertension and Sickle Cell Disease. Br. J. Haematol., 2017, 140, 104-112
[30] Hebson, C.; New, T.; Record, E.; Oster, M.; Ehrlich, A.; Border, W.; James-Herry, A.; Kanaan, U. Elevated Tricuspid Regurgitant Velocity as a Marker for Pulmonary Hypertension in Children with Sickle Cell Disease: Less Prevalent and Predictive than Previously Thought? J. Pediatr. Hematol. Oncol., 2015, 37, 134–9.
[31] Jesus-Rojas, W.; Mosquera, R.A.; DaCosta, C.; Stark, C.K.; Jon, K.; McBeth, A.; Yadav, A,; Houston, T.X. Screening of Pulmonary Hypertension in a Cohort of Children with Sickle Cell Disease. In: A62. Sickle Cell Disease. American Thoracic Society, New York, 2018. pA2057.
[32] Lamina, M.O.; Animasahun, B.A.; Akinwumi, I.N.; Njokanma, O.F. Doppler Echocardiographic Assessment of Pulmonary Artery Pressure in Children with Sickle Cell Anaemia. Cardiovasc. Diag. Ther., 2019, 9, 204–13.
[33] Liem, R.I.; Young, L.T.; Thompson, A.A. Tricuspid Regurgitant Jet Velocity is Associated with Hemolysis in Children and Young Adults with sickle Cell Disease Evaluated for Pulmonary Hypertension. Haematologica, 2007, 92, 1549–52.
[34] Liem, R.I.; Nevin, M.A.; Prestridge, A.; Young, L.T.; Thompson, A.A. Tricuspid Regurgitant Jet Velocity Elevation and its Relationship to Lung Function in Pediatric Sickle Cell Disease. Pediatr. Pulmonol., 2009, 44, 281–9.
[35] Minniti, C.P.; Sable, C.; Campbell, A.; Rana, S.; Ensing, G.; Dham, N.; Onyekwere, O.; Nouraie, M.; Kato, G.J.; Gladwin, M.T.; Castro, O.L.; Gordeuk, V.R. Elevated Tricuspid Regurgitant Jet Velocity in Children and Adolescents with Sickle cell Disease: Association with Hemolysis and Hemoglobin Oxygen Desaturation. Haematologica, 2009, 94, 340–7.
[36] Molavi, M.A.; Rajaei, S.; Elahi, Z.; Nazemi, A.; Zare, S. Evaluation of Tricuspid Regurgitation Jet Velocity in Children with Sickle Cell Disease in Iran 2012-2013. Adv. Biores., 2015, 6, 211.
[37] Mondal, P.; Stefek, B.; Sinharoy, A.; Sankoorikal, B.J.; Abu- Hasan, M.; Aluquin, V. The Association of Nocturnal Hypoxia and an Echocardiographic Measure of Pulmonary Hypertension in Children with Sickle Cell Disease. Pediatr. Res., 2019, 85, 506–10.
[38] Nelson, S.C.; Adade, B.B.; McDonough, E.A.; Moquist, K.L.; Hennessy, J.M. High Prevalence of Pulmonary Hypertension in Children with Sickle Cell Disease. J. Pediatr. Hematol. Oncol., 2007, 29, 334–7.
[39] Nouraie, M.; Darbari, D.S.; Rana, S.; Minniti, C.P.; Castro, O.L.; Luchtman-Jones, L.; Sable, C.; Dham, N.; Kato, G.J.; Gladwin, M.T.; Ensing, G.; Arteta, M.; Campbell, A.; Taylor, J.G 6th.; Nekhai, S.; Gordeuk, V.R. Tricuspid Regurgitation Velocity and Other Biomarkers of Mortality in Children, Adolescents and Young Adults with Sickle Cell Disease in the United States: The PUSH Study. Am. J. Hematol., 2020, 95, 766–74.
[40] Onalo, R.; Cooper, P.; Cilliers, A.; Nnebe-Agumadu, U. Cardiovascular Changes in Children with Sickle Cell Crisis. Cardiol. Young, 2020, 30, 162–70.
[41] Onyekwere, O.C.; Campbell, A.; Teshome, M.; Onyeagoro, S.; Sylvan, C.; Akintilo, A.; Hutchinson, S.; Ensing, G.; Gaskin, P.; Kato, G.; Rana, S.; Kwagyan, J.; Gordeuk, V.; Williams, J.; Castro, O. Pulmonary Hypertension in Children and Adolescents with Sickle Cell Disease. Pediatr. Cardiol., 2008, 29, 309–12.
[42] Pashankar, F.D.; Carbonella, J.; Bazzy-Asaad, A.; Friedman, A. Prevalence and Risk Factors of Elevated Pulmonary Artery Pressures in Children with Sickle Cell Disease. Int. J. Contemp. Pediatr., 2008, 121, 777–82.
[43] Patel, P.; Sharma, S.; Shah, N.; Manglani, M. Prevalence of Pulmonary Hypertension in Children with Sickle Cell Disease. Int. J. Contemp. Pediatr., 2016, 3, 1076–82.
[44] Peter, I.D.; Asani, M.O., Abdullahi, S.U.; Aliyu, I.; Obaro, S.K.; Bode-Thomas, F. Pulmonary Hypertension and Right Ventricular Function in Nigerian Children with Sickle Cell Anaemia. Trans. R. Soc. Trop. Med. Hyg., 2019, 113, 489–96.
[45] Qureshi, N.; Joyce, J.J.; Qi, N.; Chang, R.K. Right Ventricular Abnormalities in Sickle Cell Anemia: Evidence of a Progressive Increase in Pulmonary Vascular Resistance. J. Pediatr., 2006, 149, 23–7.
[46] Sedrak, A.; Rao, S.P.; Miller, S.T.; Hekmat, V.; Rao, M. A Prospective Appraisal of Pulmonary Hypertension in Children with Sickle Cell Disease. J. Pediatr. Hematol. Oncol., 2009, 31, 97-100.
[47] Sokunbi, O.J.; Ekure, E.N.; Temiye, E.O.; Anyanwu, R.; Okoromah, C.A.N. Pulmonary Hypertension among 5 to 18 Year Old Children with Sickle Cell Anaemia in Nigeria. PLoS One. 2017, 12, e0184287.
[48] Suell, M.N.; Bezold, L.I.; Okcu, M.F.; Mahoney, D.H. Jr.; Bertuch, A.A. Increased Pulmonary Artery Pressures among Adolescents with Sickle Cell Disease. J. Pediatr. Hematol. Oncol., 2005, 27, 654–8.
[49] Musa, B.M.; Galadanci, N.A.; Coker, M.; Bussell, S.; Aliyu, M.H. The Global Burden of Pulmonary Hypertension in Sickle Cell Disease: A Systematic Review and Meta-Analysis. Ann. Hematol., 2016, 95, 1757–64.
[50] Bigna, J.J.; Noubiap, J.J.; Nansseu, J.R.; Aminde, L.N. Prevalence and Etiologies of Pulmonary Hypertension in Africa: A Systematic Review and Meta-Analysis. BMC Pulm. Med., 2017, 17, 183.
[51] Bigna, J.J, Nansseu, J.R.; Noubiap, J.J. Pulmonary Hypertension in the Global Population of Adolescents and Adults Living with HIV: A Systematic Review and Meta-Analysis. Sci. Rep., 2019, 9, 7837.
[52] Schoenberg, N.C.; Argula, R.G.; Klings, ES.; Wilson, K.C.; Farber, H.W. Prevalence and Mortality of Pulmonary Hypertension in ESRD: A Systematic Review and Meta-Analysis. Lung. 2020, 198, 535–45.
[53] Avouac, J.; Airò, P.; Meune, C.; Beretta, L.; Dieude, P.; Caramaschi, P.; Tiev, K.; Cappelli, S.; Diot, E.; Vacca, A.; Cracowski, J.L.; Sibilia, J.; Kahan, A.; Matucci-Cerinic, M.; Allanore, Y. Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Meta-Analysis of 5 Studies. J. Rheumatol., 2010, 37, 2290–8.
[54] Rhodes, C.J.; Wharton, J.; Wilkins, M.R. Pulmonary Hypertension: Biomarkers. Handb. Exp. Pharmacol., 2013, 218, 77–103.